Hemolytic uremic syndrome.
Camp-Sorrell
Dawn
D
Hematology Oncology Associates of Alabama, Sylacauga, USA.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000188:drug therapy; D016913:Blood Component Transfusion; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D016903:Drug Monitoring / Q000451:nursing; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D016685:Mitomycin / Q000009:adverse effects*; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing; D010949:Plasma; D010956:Plasmapheresis; D035583:Rare Diseases; D006435:Renal Dialysis; D013156:Splenectomy
D000893:Anti-Inflammatory Agents; D000903:Antibiotics, Antineoplastic; D000959:Antihypertensive Agents; D016685:Mitomycin; D008775:Methylprednisolone